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DPA certification. Legislation enacted in 1 996 (SB 668,
Polanco; Chapter 1 3, Statutes of 1 996) established a certifi
cation program within the Board, whereby the Board certi
fies qualified optometrists who complete additional training
to use specific classes of therapeutic pharmaceutical agents
(TPA) for a limited number of eye conditions. [16: 1 CRLR
69J However, some optometrists who were initially licensed
before 1 980 have never applied for DPA or TPA certification.
Dr. Anthony stated that the position of the Board has been
to continue licensing non-DPA- or TPA-certified optometrists
under the assumption that their number would eventually
dwindle due to attrition. He expressed concern, however, that
current optometric practice is significantly limited and may
be inadequate without the use of pharmaceutical agents. De
spite a suggestion by Board President Steven Grant, OD, that

the Board issue a mandate requiring optometrists to receive
DPA training or lose their licenses, the B oard agreed to
further investigate the status of uncertified practitioners. Dr.
Anthony agreed to draft a letter to uncertified optometrists,
inquiring as to whether they continue active practice and
whether the nature of their practice is limited by their non
certified status. At this writing, Dr. Anthony expects to present
a draft of this letter to the Board for approval at its May
meeting.

F UTURE M E ETINGS
• May 1 6- 1 7, 1 999 in San Jose.
• August 20-2 1 , 1 999 in Sacramento.
• November 1 4- 1 5, 1 999 in San Diego.
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P

ursuant to Business and Professions Code section 4000
et seq., the Board of Pharmacy grants licenses and per
mits to pharmacists, pharmacy interns, pharmacy tech
nicians, pharmacies, pharmacy corporations, nonresident
pharmacies, wholesale drug facilities, medical device retail
ers, veterinary food-animal drug retailers, out-of-state dis
tributors, clinics, and hypodermic needle and syringe distribu
tors. It regulates all sales of dangerous drugs, controlled sub
stances, and poisons. The Board is authorized to adopt regu
lations, which are codified in Division 1 7 , Title 1 6 of the
California Code of Regulations (CCR).
To enforce the Pharmacy Law and its regulations, the
Board employs full-time inspectors who investigate com
plaints received by the Board. Investigations may be con
ducted openly or covertly as the situation demands. The Board
conducts fact-finding and disciplinary hearings, and is au
thorized by law to suspend or revoke licenses or permits for a
variety of reasons, including professional misconduct and any
misconduct substantially related to the practice of pharmacy.
The Board of Pharmacy is a consumer protection agency
located within the Department of Consumer Affairs (DCA).
The Board, which meets five times per year, consists of eleven
members, four of whom are nonlicensees. The remaining
members are pharmacists, five of whom must be active prac
titioners. All Board members are appointed for four-year
terms.

MAJOR PROJECTS
Pharmacy Practice on the Internet

Over the last few months, the Board and the public have
witnessed a surge of pharmacy practice activity on the Internet.
While the Pharmacy Law requires a pharmacy which offers
to compound, dispense, or refill a prescription for a resident
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of California to be licensed by the
Board as a nonresident pharmacy,
the Board's Licensing Committee
has requested that the Board sponsor legislation that will re
quire additional disclosure of information on the application
form specific to Internet pharmacy practice.
Currently, Deputy Attorney General William Marcus is
drafting proposed legislation based on the Licensing
Committee's discussions. The legislation would require an
Internet pharmacy to disclose specific information on its ap
plication for licensure, including its Internet name; its corpo
rate or business name (if different); the names and addresses
of its officers, directors, partners, and shareholders; and the
location of each pharmacy which will be performing com
pounding, dispensing, or refilling of prescriptions, maintain
ing or reviewing patient profiles, or providing patient con
sultation. Additionally, the applicant must provide proof that
it, and any pharmacy or pharmacist it employs or contracts
with, is licensed or registered as required by the laws of the
host state. Finally, an Internet pharmacy must provide spe
cific descriptive information to consumers on its website.

CURES Update
For several years, the Board has been involved in a multi
agency project to automate the current paper-based "tripli
cate system" used when a physician or other authorized pre
scriber prescribes, and a pharmacist dispenses, Schedule II
controlled substances. [16: 1 CRLR 69-70; 15:4 CRLR 116;
15:2&3 CRLR 89] Under the triplicate system, prescribers
must prescribe Schedule II narcotics on a state-issued tripli
cate form. The prescriber retains one copy and gives the re
maining two copies to the patient. To have the prescription
filled, the patient takes the remaining two parts of the form to
a pharmacy. The pharmacy endorses the prescription, retains
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DOJ and the B oard submitted a progress report on the
a duplicate, and checks the form for compliance with Health
data
collection project to the legislature on January 1 . Ac
and Safety Code section 1 1 206. Section 1 1 164 of the Health
cording
to the report, CURES has arrived at a key point in
and Safety Code requires the pharmacy to transmit the origi
time,
because
the Triplicate Prescription Program adminis
nal of the triplicate form to the Department of Justice's (DOJ)
tered by DOJ's Bureau of Narcotic Enforcement has been
Triplicate Prescription Program at the end of the month in
unable to process the vastly increasing number of Schedule
which the prescription was filled. The purpose of the tripli
II controlled substance prescriptions dispensed in Califor
cate system is to monitor closely the prescribing and dispens
nia. By the end of 1998, approximately 105,000 California
ing of Schedule II controlled substances to control effectively
practitioners were eligible to obtain triplicate prescription
the abuse and diversion of these narcotics while allowing
forms and prescribe Schedule II controlled substances. Also
patient access to appropriate medications. However, prescrib
in 1 99 8 , those practitioners issued over 2 .29 million
ers and dispensers complain that the paper-intensive tripli
Schedule II prescriptions. In that same year, however, the
cate system is burdensome in light of modern electronic
Triplicate Prescription Program was able to process only
recordkeeping methods.
39,945 such prescriptions into its existing outmoded auto
AB 3042 (Takasugi) (Chapter 738, Statutes of 1 996)
mated system (down from 256,303 in 1995). During the first
added section 1 1 165 to the Health and Safety Code, which
seven months in which CURES was operational, it was able
requires the Board of Pharmacy and DOJ to establish the
to process a total of 892,985 triplicate prescription forms
Controlled Substance Utilization Review and Evaluation Sys
transmitted by pharmacies.
tem (CURES) to electronically monitor the prescribing and
The progress report states that CURES has had a neglidispensing of Schedule II controlled substances by all practi
gible impact on pharmacists.
tioners authorized to prescribe or
dispense them. AB 3042 requires CU RES has arrived at a key point in time, Computer technology and stan
that CURES be implemented as a because the Triplicate Prescription Program dardization is already an integral
three-year pilot project commenc adm i n istered by DOJ's Bureau of N arcotic part of the pharmacy i ndustry,
ing on July 1 , 1997, to be admin Enforcement has been unable to process the making pharmacies comfortable
istered concurrently with the ex vastly i n c re asi ng n u m be r of Sched u l e I I with and receptive to the use of
isting triplicate system, to exam controlled substance prescriptions dispensed automation in performing their
daily tasks. Approximately 95%
ine the comparative efficiencies in Cal ifornia.
of the 5,000 pharmacies in Cali
between the two systems. Thus,
the statute requires DOJ and the Board to engage in a major
fornia are computerized. CURES has had no impact on pre
scribers, as they continue to write Schedule II prescriptions
data collection process to determine the relative efficiencies
as they always have.
of the existing triplicate system and the electronic mainte
nance of Schedule II narcotics data. The data received from
A second objective of CURES is to provide flexible
the state's 5,000 pharmacies are made available online to DOJ,
data analysis to prevent drug diversion according to the
the Board, the Medical Board, the Board of Dental Examin
specialized information requirements of each governmen
ers, and the Osteopathic Medical Board of California.
tal user. Through a private contractor, CURES provides
To facilitate the collection of the required data, the Board
the flexibility of using standardized output reports or the
option of customizing data output according to the needs
adopted section 1 7 1 5.5, Title 1 6 of the CCR, in 1998. Sec
tion 17 15.5 requires a dispensing pharmacy to provide speci
of each agency.
fied information on the patient, prescriber, and pharmacy for
The progress report also made several recommenda
each prescription of a Schedule II controlled substance; speci
tions, including the following: ( 1 ) eventually, legislation es
fies the format in which the information is to be provided;
tablishing CURES as a permanent operational program
establishes the timeframe for submitting information; pro
should be pursued; (2) existing Triplicate Prescription Pro
gram staff should be reclassified to other positions more
vides an alternate method of submission and threshold re
porting requirements for pharmacies without electronic re
suitable to the investigative and analytical duties they will
perform for CURES; (3) the program should continue to
porting capability; specifies the reporting requirements for
partially filled or dispensed prescriptions; and sets the com
capture only information on Schedule II controlled sub
pliance date for submission of information. The Board con
stances, but it should begin to evaluate the feasibility of
tracted with Atlantic Associates, Inc. in Manchester, New
collecting Schedules III-V controlled substances prescrip
Hampshire to collect all the information, and mailed several
tion data as well; and (4) the CURES database should even
notices (with a CURES handbook) to all California pharma
tually be expanded to include information received by the
cies about the new reporting requirements. The Board warned
Board pursuant to section 1782, Title I 6 of the CCR, re
pharmacies that CURES is operating concurrently with the
garding excessive sales of drugs that are subject to abuse.
existing triplicate prescription program; thus, pharmacies are
The Board has already submitted proposed legislation which
still required to mail original triplicate prescription forms to
will continue to fund CURES and extend it until 2003 (see
DOJ at the end of each month.
LEGISLATION).
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Board Proposes Regulations Governing
Specialized Refill Pharmacies

possibility that an applicant for a medical device retailer per
mit would use his/her personal residence or the residence of
someone else as a licensed premise. Section 1 748.3 would
explicitly prohibit a medical device retailer from conducting
business from a private residence. In addition, section 1 748.3
would prohibit a medical device retailer from locating a ware
house, the primary purpose of which is storage of medical
devices, at a private residence.
At this writing, the Board does not intend to hold a pub
lic hearing on its proposed adoption of section 1 748.3. How
ever, it is accepting written comments until May 3.

Recently, many new pharmacy operations and concepts
have begun to emerge. One such concept is a refill pharmacy,
which prepares refill prescriptions for another pharmacy.
While the B oard has licensed such pharmacies in the past, it
has determined that labeling and documentation requirements
should be established to assure that patients can readily de
termine where the prescription was filled . Specifically, phar
macies that receive an original prescription for filling some
times use another pharmacy for refills. The B oard bel ieves
Furnishing of Drugs and Devices by
that this use of a refill pharmacy may result in confusion to
patients who receive medications and who do not know which
Wholesalers and Manufacturers
pharmacy actually provided the medication or whom to con
Drug diversion is the illicit distribution, prescribing,
tact. This would be especially critical if the medication is dis
dispensing, or use of controlled substances that are manu
pensed in error or in a form not readily identifiable to the
factured and intended for leg itimate purposes. One of the
patient. Further, the B oard believes that the labeling and
way s in which the B oard guards against drug diversion is
recordkeeping practices by both pharmacies should be con
by rev iewing the records of drug wholesalers and manu
sistent, to assure that patient safety and confidential ity are
facturers for compl iance with the Pharmacy Law. The
maintained.
records of sale, purchase, and
On February 26, the B oard
disposition of dangerous drugs
published notice of its intent to Section 1 74 8 . 3 would expli citly p ro h i b i t a and devices are required to be
adopt section 1 707.4, Title 16 of medical device retai l e r fro m cond ucting made avail able , at all times
business from a private residence.
the CCR, to address its concerns
during business hours, for inabout the use of refill pharmacies.
spect ion by author ized law
The purpose of the Board's proposal is to ( I ) allow a phar
enforcement officers. All persons who are involved in drug
macy to utilize the services of another pharmacy to provide
transactions must be licensees (or their designated agents)
refills if it has a contract for these services or has common
of the B oard or an other governmental agency. When
ownership; (2) specify the labeling requirements for a prescrip
unauthorized persons are involved in drug transactions, the
tion refilled at a refill pharmacy, including the name of the
public health, safety, and welfare are put at risk.
refill pharmacy and which pharmacy the patient should con
The potential for drug diversion arises when drugs are
tact if he/she has questions (this information may be either on
received from manufacturers or wholesalers by non-licensed
the label or in writing accompanying the medication); (3)
persons. According to the Board, these non-licensed individu
specify the documentation requirements for the originating
als frequently divert the drugs for illegal use or sale. These
pharmacy and the refill pharmacy; and (4) allow a pharmacy
drugs may not be maintained according to manufacturers'
to operate as a refill pharmacy as well as fill new prescriptions.
specifications, which can result in harm to patients. Further,
At this writing, the B oard is scheduled to hold a publ ic
payment for these drugs may involve non-licensed parties
hearing on its proposal to adopt section 1707.4 on May 19.
whose interest in the transaction is fraudulent. According to
the B oard, these individuals use Board-licensed owners of
Medical Device Retailer Location Restrictions
closed-door pharmacies which they set up to operate "straw
One way in which the B oard protects consumers is by
man" businesses. The drugs purchased at the wholesale dis
reviewing the records of medical device retailers and medi
count allowed for this type of pharmacy are then sold on the
cal device retailer warehouses. Business and Professions Code
black market.
On March 19, the B oard publ ished notice of its intent to
section 4 1 32(f) requires medical device retailers to make their
records of sale, purchase, and disposition of dangerous de
adopt section 1 783, Title 1 6 of the CCR, to eliminate any
confusion on the part of drug wholesalers and manufacturers
vices available, at all times during business hours, for inspec
regarding with whom they may make arrangements for the
tion by authorized law enforcement officers. When persons
purchase and delivery of drugs, and to ensure that these drugs
conduct a medical device retail business from their home or
are maintained at all times by licensees or their designated
the home of someone else, Pharmacy Board inspectors and
agents. Section 1 783 would define the term "authorized per
authorized law enforcement officers have encountered prob
son" to clarify for law enforcement purposes to whom whole
lems gaining access to records because of residential privacy
salers may furnish drugs and from whom they may accept
issues.
payment for drugs. "Authorized person" means a person to
On March 1 9, the Board published notice of its intent to
whom the B oard has issued a permit to purchase dangerous
adopt section 1 748.3, Title 1 6 of the CCR, to eliminate the
50
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drugs or devices for use within the scope of the permit and
any person so authorized by the law of another state or
federal law. Section 1 783 would also include provisions
authorizing delivery of drugs to an agent of an authorized per
son under specified circumstances, allowing delivery of drugs
to a hospital pharmacy receiving area under specified circum
stances, establishing financial arrangements criteria for whole
salers and manufacturers to accept payment for drugs, and es
tablishing recordkeeping requirements for all parties involved.
At this writing, the Board does not intend to hold a pub
lic hearing on its proposed adoption of section 1 783. How
ever, it is accepting written comments until May 3.
Board Reduces Licensing Fees

At its January 20 meeting, the Board adopted section 1 749
and amended section 1 749. 1 , Title 1 6 of the CCR, to reduce
most of its licensing fees effective July 1 . This action will
enable the Board to reduce its reserve fund to approximately
one year's expenditures, as required by law. [1 6: 1 CRLR 73]
The Board, however, withdrew its proposed amend
ment to section 1 793.5, which would have reduced initial
pharmacy technician registration fees from $50 to $25 . The
Board based this action on a fee audit report presented at
the meeting by Market Value Planners, which was commis
sioned by the Board to analyze the Board's licensing fee
structure to determine whether fees are appropriate for the
recovery of the actual cost of conducting its various pro
grams. The report documented that the $50 fee charged for
pharmacy technician registration is well below the Board's
$ 1 43 cost of processing the application; thus, a reduction
would be inappropriate.
The Office of Administrative Law approved the Board's
amendments on April 20.
Restocking ofAmbulances with Supplies and
Medications

At its October 1998 meeting, the Board agreed to con
vene a multi-agency task force to explore legal issues related
to the restocking of ambulance supplies (including drugs) by
hospitals. An advisory opinion from the Health Care Financ
ing Administration's Office of the Inspector General, which
concluded that a hospital 's restocking of ambulance supplies
likely violates federal anti-kickback law and raises antitrust,
tax, pharmacy, contract, and False Claims Act issues,
prompted hospitals to discontinue restocking ambulances with
supplies and drugs. In turn, some ambulances began to pur
chase, store, and restock medications and supplies; for con
trolled narcotics, they were using the license and DEA cer
tificate of their contracted medical director. Because the Board
does not believe the Pharmacy Law permits this practice, it
decided to convene the task force with representatives from
the Department of Health Services (DHS) and the Emergency
Medical Services Authority (EMSA). [ 16: 1 CRLR 71 J
At its March meeting, the Board approved a report and
recommendation of its Licensing Committee that the Board

sponsor legislation to authorize the restocking of ambulances
by hospital pharmacies and by other providers if certain
requirements are met. For example, the purchase of drugs
and devices would be under the authority of the local emer
gency medical services director, and the licensed emergency
medical technician and/or paramedic would be responsible
for the maintenance and recordkeeping of the dangerous drug
and device stock.
At this writing, the Board is still working with DHS and
EMSA to draft appropriate language for the legislation.
Implementation of the FDA Modernization
Act of 1 99 7

The FDA Modernization Act o f 1997, which became ef
fective in November 1 998, requires FDA and the fifty states
to enter into a memorandum of understanding (MOU) regard
ing the compounding of drugs. Compounding is the process
by which a pharmacist combines, mixes, or alters ingredients
to specialize a medication for a patient, at the direction of a
physician. Section 503A of the Act recognizes compounding
as an element of the practice of pharmacy that is to be regu
lated by the states, and distinguishes it from "manufactur
ing" which falls within the jurisdiction of the FDA. The pur
pose of the section is "to ensure continued availability of com
pounded drug products as a component of individualized
therapy, while limiting the scope of compounding so as to
prevent manufacturing under the guise of compounding." The
purpose of the MOU is to address the interstate distribution
of "inordinate amounts" of compounded drug products and
the related issue of state investigations of complaints regard
ing this distribution.
The law instructs the FDA and the National Association
of Boards of Pharmacy (NABP) to develop a standard MOU
for state boards. The goal of the MOU is to obtain state agree
ment on two issues: ( 1 ) protocols for the appropriate investi
gation of complaints relating to compounded drug products
shipped out-of-state; and (2) establishment of appropriate
restrictions on the amount of compounded drugs shipped in
interstate commerce, including "safe harbors" for pharma
cists who distribute compounded products in interstate com
merce. Pharmacies located in a state that did not sign an MOU
by the law's effective date (November 2 1 , 1998) are subject
to FDA's "safe harbor" provision, whereby compounded prod
ucts may not exceed 5% of the total prescription orders dis
pensed or distributed by that pharmacy. [16: 1 CRLR 71-72]
At its March meeting, the Licensing Committee advised
the Board that NABP circulated a draft MOU for comment in
January. Once FDA adopts the final version of the MOU, the
Board will consider it, along with the Licensing Committee's
recommendation that the Board sign it.

LEG I SLAT I O N
SB 1308 (Committee on Business and Professions), as
amended April 1 4, would enact various technical changes
affecting licensing boards within DCA. Several of the bill's
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research, and extend the program until July 1 , 2003 (see
provisions would amend the Pharmacy Act in the Business
MAJOR PROJECTS). The bill would require the Board
and Professions Code, including the following:
• SB 1 308 would amend section 4008 to require the salary
to subm i t to the legislature annual reports on the
effectiveness of the CURES program on January 1 , 2000,
of the Board's inspectors who are pharmacists to be within
200 1 , and 2002. [S. Appr]
5% parity of pharmacists employed by the University of
California.
AB 141 (Knox), as introduced on January 1 1 , would
• The bill would amend section 4022 to revise the defini
require the Board to conduct a study of the incidence of
tion of "dangerous drug or device" to include drugs or
medication errors in pharmacies in California, employing a
devices bearing the statement "Rx only." This change
methodology that uses "test" prescriptions distributed to a
would conform California's definition of "dangerous drug
statistically significant cross-section of pharmacies in the
or device" to the federal definition.
state. The bill would define a "test" prescription as one that
is prepared solely for the purposes of this study and not for
• SB 1 308 would add section 4040.5 to the Code to define
the actual medical needs of a
"reverse distributor" as a perpatient, and would require all
son who acts as an agent for
AB 1 4 1 (Knox), as introduced on J anuary 1 1 ,
"test" prescription drugs, after
pharmacies, drug wholesalers,
would require the Board to conduct a study examination for purposes of the
manufacturers, and other entiof the inci dence of m e d i c ation errors i n study, to be forwarded to the
ties by receiving, inventorying,
pharmacies in California.
Board to remain in its custody
and managing the disposition
until destroyed. The bill would
of outdated or nonsalable conrequire the Board, in designing the study, to confer with the
trolled substances. The bill would amend section 4043 to
scientific and academic community to ensure that the study
expand the definition of "wholesaler" to include a "cus
is based on sound scientific and analytic principles. The
toms broker" and "reverse distributor," thus requiring cus
study is designed to measure the frequency and describe the
toms brokers and reverse distributors to be licensed as drug
type of medication errors occurring in California, to improve
wholesalers.
patient
safety, and to identify broader issues that may be
• The bill would amend section 4057 to permit the Board to
come
the
basis for instituting profession-wide standards and
control through regulations (rather than statute) items that
changes
(see
RECENT MEETINGS). AB 1 4 1 would also
may be stored outside a pharmacy's licensed premises.
require the Board to issue a report of its findings from the
• SB 1 308 would amend section 4078 to permit a pharma
study to the legislature by December 1 , 2002.
cist to place a false label on a prescription if the labeling
Last year, Governor Wilson vetoed AB 1 889 (Knox), a
is a necessary part of a clinical or investigational drug
similar bill. In his veto message, the Governor stated that the
program approved by the FDA or a legitimate investiga
bill's reference to "placebo" prescriptions was inappropriate,
tional drug project involving a drug previously approved
and that any such study should use the term "fictitious" rather
by the FDA. The bill would also permit false labeling in
than "placebo" to describe prescriptions. AB 1 4 1 addresses
situations where, in the medical judgment of the prescriber,
that concern by using the term "test." Governor Wilson also
the labeling is necessary for the proper treatment of the
suggested that a study of this problem could by done by na
patient.
tional organizations rather than the Board. [ 16: 1 CRLR 75)
• The bill would amend section 4204 to allow a pharmacist
At its March 24 meeting, the Board voted (with pharma
to perform skin .puncture in the performance of routine
cist member Darlene Fujimoto abstaining) to support AB 1 4 1
drug therapy-related patient assessment procedures. Ex
i n concept, but t o withhold its full support pending appropri
isting law limits a pharmacist's performance of skin punc
ate amendments allocating funding for the study and ensur
ture to skin puncture for the purposes of training and as
ing the confidentiality of those who participate in the study.
sisting patients or to monitor medical conditions (includ
[A. Appr)
ing diabetes). SB 1 308 would remove these limitations.
AB 261 (Lempert), as introduced on February 3, would
permit physicians and pharmacists to enter into protocols
• SB 1 308 would also amend section 4202 to require an
under which pharmacists could adjust patients' drug therapy.
applicant for registration as a pharmacy technician to be a
Under existing law, pharmacists may adjust patients' drug
high school graduate or to possess a general education
therapy
only in specified practice settings and for home health
development equivalent.
care and patients covered by managed care plans.
• Section 4402 would be amended to provide for the can
Under AB 26 1 , protocols for drug therapy would be de
cellation oflicenses which are not renewed within 60 days
veloped by health professionals, including physicians, phar
by the Board, rather than by operation of law.
macists, and registered nurses. At minimum, the protocol
• Finally, SB 1 308 would amend section 1 1 1 65 of the Health
must require that the medical records of the patient be
and Safety Code to expand the purposes of the CURES
available to both the patient ' s prescriber and the phar
program to include statistical analysis, education, and
macist, and that the procedures to be performed by the
52
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pharmacist relate to a condition for which the patient has
first seen a physician. AB 26 1 would permit a pharmacist
to order or perform routine drug therapy-related patient
assessment procedures (including temperature, pulse, and
respiration), order drug therapy-related laboratory tests,
administer drugs and biological s by injection pursuant to a
prescriber's order, and adjust the drug regimen of a patient
pursuant to a specific written order or authorization made
by the patient's prescriber for the individual patient and in
accordance with the protocol. AB 26 1 also would allow a
patient's prescriber to prohibit, by written instruction, any
adj ustment or change in the patient's drug regimen by the
pharmacist. Finally, the bill would require the pharmacist
to provide to the supervising physician in writing any change,
adjustment, or modification of an approved preexisting treat
ment or drug therapy within 24 hours.
AB 26 1 is sponsored by the California Pharmacists As
sociation (CPhA) and is opposed by the California Medical
Association. At its March 24 meetiri'g, the Board voted unani
mously to support AB 26 1 . [A. Health}
AB 1496 (Olberg), as amended on April 14, would add
section 4052.5 to the B usiness and Professions Code to
establish a new "home medical equipment services provider"
(HMESP) licensure category under the Board to replace the
"medical device retailer" category, and expand the definition
of those who must be licensed as home medical equipment
services pro v i ders. S pecifi c al l y, AB 1 496 would
replace references to "medical device retailer" with the term
"HMESP" to create a new category of licensure, and define
an HMESP as an individual, entity, or corporation engaged
in the business of providing home medical equipment ser
vices to unrelated sick or disabled individuals where those
individuals reside. AB 1 496 would define "home medical
equipment" as technologically sophisticated medical devices
usable in a home care setting, including but not limited to
oxygen and oxygen delivery systems, ventilators, continuous
positive airway pressure devices, respiratory disease manage
ment services, hospital beds and commodes, electronic and
computer-driven wheelchairs and seating systems, apnea
monitors, dangerous devices, distribution of medical gases
to end users for human consumption, and any other similar
equipment as defined by regulations adopted by the Board.
AB 1 496 would require HMESP licensees to have emer
gency services available 24 hours per day, 365 days per year,
for equipment maintenance if equipment malfunction would
threaten a patient's health. The bill would exempt HMESP lic
ensees that dispense or provide hospital beds or wheelchairs
pursuant to a prescription from paying licensing fees as bed
ding or furniture dealers. Additionally, the bill would exempt
from HMESP licensure specified entities and practitioners who
already have various licenses, unless the entities or practitio
ners furnish home medical equipment services through a sepa
rate entity. These exemptions include certain home health agen
cies, hospitals, pharmacies, hospice programs, nursing homes,
veterinarians, dentists, and emergency medical services.

The bill's sponsor, the California Association of Medi
cal Products Suppliers (CAMPS), asserts that consolidating
home medical equipment providers' licensure requirements
"under one roof' will increase efficiency and reduce costs.
CAMPS further argues that a consolidated form of licensure
will improve public safety as there has been significant growth
in home health care and increased sophistication in the types
of care, equipment, and supplies used in the home. Accord
ing to CAMPS, current law provides inadequate protection
of consumers because it fails to specify what type of equip
ment or supplies must be regulated but merely refers to the
presence of a warning label. Specifically, existing law de
fines "dangerous device" as any device unsafe for self-use,
including any device that bears the statement "Caution: Fed
eral law restricts this device to sale by or on the order of a
[blank] ," with the blank to be filled in with the designation of
the practitioner licensed to use or order use of the device.
Finally, CAMPS argues that the expanded licensure scope
will curb Medicare and Medi-Cal fraud in the provision of
home medical equipment services.
At its March 24 meeting, the B oard took an "oppose un
less amended" position on AB 1 496. According to the Board,
in the eight years it has licensed medical device retailers, it
has not received complaints from patients regarding the
services and equipment provided by medical device retailers.
Instead, its sole enforcement activity has been to investigate
complaints of unlicensed activity filed by licensed medical
device retailers. The Board contends that if the intent behind
AB 1496 is to combat fraud against the Medi-Cal program,
the bill should be amended to move the licensing and regula
tion of the "home medical equipment services providers" listed
in the bill to OHS, which is responsible for the Medi-Cal
program. [A. Appr}
AB 660 (Cardenas). Existing law generally prohib
its a person from dispensing a prescription unless he/she
is a pharmacist, in which case a prescription must be given
to the pharmacist. However, a pharmacist may refill a
prescription without the prescriber 's authorization if the
prescriber i s unavailable to authorize the refill and if, in
the pharmacist's professional judgment, failure to refill
the prescription may i n terrupt the patient ' s ongoing care
and have a significant adverse effect on the patient's well
being.
As amended April 28, AB 660 would specify that, dur
ing the period commencing November 1 , 1 999 and ending
February 29, 2000, ( 1 ) a prescriber is deemed unavailable
to authorize a refill if confronted with problems caused by
computer fai lures arising from the inability of computers to
properly handle dates; and (2) a pharmacist may refill a pre
scription, based upon a request made by the patient who is
taking the medication, for up to and including 90 days from
the date of the request. The purpose of the bill is to ensure
that possible delays in the refills of patient prescriptions will
not further complicate potential impacts on public safety
caused by the Y2K problem. [A. Floor]
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AB 724 (Dutra), as amended April 27, would provide
that, notwithstanding any other provision of law, during the
period commencing December 1 , 1 999, and ending Febru
ary l , 2000, a pharmacist shall refill any refillable prescrip
tion with medication sufficient for a period up to and
including 60 days, subject to the number and terms of
authorized refills, upon request of the person on whose
behalf the prescription was written. The bill would autho
rize a pharmacist, during that same period, to refill any
refillable prescription with medication sufficient for a pe
riod up to and including 60 days, subject to the number and
terms of authorized refills, if the pharmacist determines that
it is necessary to fill the prescription for the extended
period to prevent possible harm to the person on whose be
half the prescription was written that might result from a
Y2K problem complication or failure, or the potential for
those events. [A. Appr]
SB 404 (Alpert), as amended March 1 8, would autho
rize a pharmacist to initiate emergency contraception drug
therapy in accordance with written guidelines or protocols
previously established and approved for his/her practice by a
practitioner authorized to prescribe drugs. [S. B&P J
AB 1430 (Bates), as amended April 23, would make a
number of changes relating to the prescription and receipt of
drugs by Board licensees. Under existing law, dangerous drugs
or devices ordered by an entity licensed by the Board must be
delivered to the licensed premises and signed for and received
by the pharmacist-in-charge or other designated person. A
dangerous drug or device transferred, sold, or delivered to
any person in the state may only be transferred, sold, or de
livered to an entity licensed by the Board, to a manufacturer,
or to an ultimate user or the ultimate user's agent. AB 1 430
would provide that, when dangerous drugs or dangerous
devices are ordered for an entity licensed by the Board and
delivered to the licensed premises, those drugs or devices must
be signed for and received by a pharmacist licensed by the
Board. The bill would make a similar, related change with
respect to the delivery of dangerous drugs or devices to a
hospital pharmacy. The bill would also permit a dangerous
drug or device to be transferred, sold, or delivered to any
entity authorized by law to possess or handle dangerous
devices.
Existing law requires that oral and electronic data trans
mission of prescriptions be reduced to writing. AB 1 430
would eliminate that requirement, so long as a hard copy
can be produced upon request. The bill would also autho
rize prescribers and pharmacists to enter prescriptions and
orders directly into a pharmacy's or hospital 's computer from
any location, with permission of the pharmacy or hospital.
The bill would similarly permit a prescriber to authorize
his/her agent to enter a prescription on his/her behalf
directly into a furnisher's computer, with permission of the
furnisher.
Existing law requires, within 24 hours after any purchaser
in this state gives any order for a Schedule II controlled
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substance to an out-of-state wholesaler or manufacturer for
delivery in this state, that the purchaser forward to the Attor
ney General, by registered mail, a copy of the order. AB 1 430
would end that requirement.
This bill is sponsored by Kaiser Permanente and is
supported by CPhA. According to Kaiser, this bill would
expedite access to prescription medications while decreas
ing errors and lowering the cost of medical care by allow
ing physicians and their authorized agents and pharmacists
to transmit prescriptions and hospital medication orders
directly to a hospital or pharmacy computer from wherever
they are. According to Kaiser, it will also allow electronic
storage of such orders and prescriptions instead of error
prone and costly paper storage. Kaiser also states that the
bill will enable physicians, and other groups of practitio
ners, to order, receive, and use prescription medication
supplies as a group, instead of requiring each individual to
pay for and use his/her own supply. Kaiser further argues
that this bill will keep pharmacists from being interrupted
from patient-care duties just to sign a delivery sheet when
another person licensed by the B oard could sign for the
delivery. Finally, Kaiser states that this bill would repeal an
u n u s ed and u n necessary req u i rement for reporting
out-of-state controlled substance purchase and shipment
transactions to the Attorney General. According to Kaiser,
this provision was never enforced, and if it were enforced it
would provide no benefit and add substantial cost to the
health care system. [A. Appr]
SB 838 (Figueroa), as amended April 28, would allow
the Board to register a nonresident pharmacy that is orga
nized as a limited liability company (LLC) in the state in which
it is licensed.
Merck-Medco Managed Care is sponsoring this bill to
clarify that the Board may continue its long-standing prac
tice of registering nonresident pharmacies that are organized
as LLCs in their home states. An LLC-a hybrid between a
partnership and a corporation-is a relatively new form of
business organization in California. The Board registered out
of-state LLC pharmacies at least through 1 997. At that time,
DCA analyzed some uncodified language in the LLC law
which prohibits the organization of an LLC for the rendering
of professional services. Based on DCA advice, the Board
began to reject licensure applications from out-of-state LLC
pharmacies. [ I 6: 1 CRLR 70-7 I] The sponsor and its sup
porters maintain that this bill will clarify ambiguity created
by issuance of various legal opinions on the topic, and that
certainty in the law is necessary in order to continue to pro
vide low-cost mail order medications. [S. B&PJ
SB 188 (Leslie). Existing law generally prohibits any
person from selling or dispensing any dangerous drug, or
dispensing any prescription, unless he/she is a licensed phar
macist. However, a licensed hospital that contains 1 00 beds
or fewer and does not employ a full-time pharmacist may
purchase drugs at wholesale for administration, under
the direction of a physician, to patients registered in the
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hospital or to emergency cases under treatment in the hos
pital. These hospital drug dispensing activities operate un
der a so-called "limited drug room license." As amended
April 6, SB 1 88 would authorize hospitals that have a lim
ited drug room license and that meet the statutory defini
tion of a "small and rural hospital" to dispense drugs to out
patients under limited circumstances. The bill would limit
those circumstances to cases where a physician determines
that a particular drug regimen must be immediately initi
ated or continued; the physician reasonably believes that a
retail pharmacy outside the hospital is not available within
a 30 mile radi us or within 30 minutes of travel as measured
by the mode of travel the patient will employ; the quantity
of drugs dispensed is limited to the amount needed to as
sure necessary and uninterrupted therapy while the drugs
are not readily available; and the physician dispensing the
drugs has complied with the discl osure and labeling require
ments applicable to dispensing at a pharmacy. The bill would
also require hospitals that utilize this new procedure for
dispensing drugs to outpatients to have a pharmacist con
sultant to monitor and review the dispensing operation. The
bill is designed to assure patients in rural areas that their
needs fo r medication can be met in a reasonable manner.
[A. Health]

RECENT MEETI NGS

At the Board's January meeting, the Licensing Commit
tee recommended that the B oard initiate the rulemaking pro
cess to amend section 17 1 4, Title 1 6 of the CCR, to authorize
pharmacies to establish a "drive-through" portion separate from
the licensed pharmacy premise so long as ( 1 ) the pneumatic
tube used to transport the prescriptions and medication from
the pharmacy to the consumer is secure, and (2) the drive
through includes a confidential two-way video and audio com
munication capability to enable the pharmacist to engage in
oral consultation. However, Deputy Attorney General Bill
Marcus advised the Board that the proposal does not conflict
with current law and does not require regulatory changes. Thus,
the Board adopted the following policy statement: "The Board
recognizes that an increasing number of pharmacies employ
or intend to employ drive-through pharmacies for physical
delivery of prescribed drugs to patients. Any pharmacy doing
so should remember that it must comply with all the laws and
regulations governing pharmacy, including: ensuring compli
ance with laws and regulations governing patient profiles,
patient consultation, privacy and confidentiality, and the secu
rity and dispensing or refilling of prescription drugs."

At the Board's March meeting, Richard Abood, R.Ph.,
J.D., Professor of Pharmacy Practice at the University of the
Pacific School of Pharmacy, gave a presentation to the B oard
on the important issue of prescription errors. Dr. Abood re
ported the results of a recent pharmacist error survey in which
53% of the pharmacists surveyed admitted to committing a
drug error within the prior 60 days. According to the survey,
wrong drugs and wrong dosages accounted fo r over 80% of
the pharmacists' errors. Over 85% of chain pharmacists and
66% of independent pharmacists cited workload issues, and
53% of the respondents cited look-alike or sound-alike drug
names, as the reason fo r their errors.
Dr. Abood's presentati on focused on the legal ramifi
cations of prescription errors. He noted that the current trend
has been for courts to hold pharmacists to an increasingly
higher standard of care regardin g pharmacist judgment, and
to hold corporations liable under a theory of corporate neg
ligence for the acts of pharmaci sts employed by them. Dr.
Abood spoke briefly about ways to manage the risk of
liability to pharmacists and harm to patients. He noted that
pharmaci sts are often discouraged from reporting their
errors immediately by the overzealous disciplinary actions
taken by state boards of pharmacy and employers. He
stressed the need fo r developing quality assurance plans that
provide incentives to pharmacists to report their errors and
address the problems of workload which lead to prescrip
tion errors.
As noted above, a majority of the B oard voted to support
AB 141 (Knox), which would require the Board to conduct a
study of the incidence of medication errors in pharmacies in
California. The Board hopes to i dentify what types of medi
cation errors are occurring and to develop regulatory stan
dards and changes targeted at such errors to improve patient
safety. Further, the B oard devoted the April 1 999 issue of its
Script licensee newsletter to the issue of medication error re
porting. Finally, the Legislation and Regulation Committee
is currently developing, at the direction of the Board, regula
tory changes which would require pharmacies to implement
a quality assurance program to address and prevent the recur
rence of prescription errors.

FUTURE MEETI NGS

• May 1 9-20, 1 999 i n San Diego.
• July 28-29, 1 999 in San Francisco.
• October 20-2 1 , 1 999 in Sacramento.
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